Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Impact of donor age on transplant outcomes in unrelated allogeneic hematopoietic stem cell transplantation using post-transplant cyclophosphamide-based gvhd prophylaxis

View Full Paper
Ask AI
Bookmark
Share

Authors

MAMuhammad Kashif AminHealth Innovations (United States)MSMoazzam ShahzadUniversity of South FloridaAZAsma ZakirHealth Care Foundation of Greater Kansas City

Discussion

Loading...

Member takes

Overview

Retrospective analysis shows donor age slightly affects incidence of graft-versus-host disease in transplant recipients, suggesting implications for donor selection.

Key Points

  • This research evaluates how donor age influences transplant outcomes for recipients of unrelated allogeneic hematopoietic stem cell transplantation (allo-HCT).
  • Conducted a retrospective multicenter analysis using CIBMTR registry data from 2017 to 2021.
  • Included adult patients with acute myeloid leukemia or myelodysplastic syndromes undergoing first unrelated donor allo-HCT with PTCy-based GVHD prophylaxis.
  • Patients were stratified by donor age (≤30 years vs. >30 years) and various transplant outcomes were assessed.
  • Donor age was not significantly associated with overall survival, relapse, non-relapse mortality, or chronic GVHD outcomes.
  • Younger donors (≤30 years) were associated with a lower incidence of grade II–IV acute GVHD.
  • The incidence of relapse and GRFS were similar across donor age groups.

Cite This Study

Amin et al. (2025) studied this question.

synapsesocial.com/papers/69362f6c4fa91c937236dfbdhttps://doi.org/10.1182/blood-2025-173
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Differentiating donor age on AML patient outcomes in the post-transplant cyclophosphamide contemporary era.2026
  2. 2Older donor age is not associated with inferior survival in contemporary haploidentical transplantation2025
  3. 3Outcomes after unrelated donor allogeneic hematopoietic cell transplantation in age ≥65 using post-transplant cyclophosphamide.2026
  4. 4Donor Age ≥30 Years as an Independent Predictor of Inferior Outcomes After Haploidentical Hematopoietic Cell Transplantation in Acute Myeloid Leukemia. Study Conducted on Behalf of GETH-TC2025
  5. 5Donor age as an independent predictor of inferior outcomes after haploidentical hematopoietic cell transplantation in acute myeloid leukemia. Study conducted on behalf of GETH-TC2025 · 1 citations